内部人交易记录
其他尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the complete record of transactions filed by Kayyem Jon Faiz. Insider active across 4 companies, notably Inhibrx, Inc.. Cumulatively, 24 reports have been logged. Split: 5 buys · 6 sells. Total volume traded: €3.6m. History available since 2 August 2022. The latest transaction was disclosed on 8 September 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Kayyem Jon Faiz
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报24 总计
5,000 股@ US$113.5160.047% mcap17.5% 占其流量Common StockSEC:0001366268-26-000004:0
90,000 股0Common StockSEC:0002007919-25-000025:0
500,000 股0Common StockSEC:0002007919-24-000068:0
52,000 股0Common StockSEC:0002007919-24-000066:0
34,843 股@ US$14.226920.4% 占其流量Common StockSEC:0002007919-24-000064:0
89,050 股0Common StockSEC:0002007919-24-000024:0
49,284 股@ US$17.2334.0% 占其流量Common StockSEC:0002007919-24-000008:0
70,193 股@ US$16.1445.6% 占其流量Common StockSEC:0002007919-24-000006:0
3,224,301 股@ US$30.0099.3% 占其流量Common StockSEC:0000950142-24-001499:0
806,075 股Common StockSEC:0000950142-24-001492:0
6,172 股@ US$1.624.5% 占其流量Common StockSEC:0000905148-23-000622:0
145,833 股Common StockSEC:0001140361-23-016261:0
9,500 股@ US$25.26310.2% 占其流量Common StockSEC:0001739614-23-000008:0
7,541 股@ US$26.86530.2% 占其流量Common StockSEC:0001739614-22-000132:0
31,619 股Common StockSEC:0001140361-22-046669:0
2,733 股@ US$29.32790.1% 占其流量Common StockSEC:0001739614-22-000126:0
173,913 股@ US$1.1595.5% 占其流量Common StockSEC:0001140361-22-042596:0
3,572 股@ US$29.38890.1% 占其流量Common StockSEC:0001739614-22-000109:0
11,900 股0Common StockSEC:0001739614-22-000093:0
3,400 股0Common StockSEC:0001739614-22-000086:0
118,500 股0Common StockSEC:0001739614-22-000075:0
1,916 股Common StockSEC:0001487371-16-000207:0
169 股Common StockSEC:0001487371-16-000189:0
78 股Common StockSEC:0001487371-16-000189:1
About Kayyem Jon Faiz
Kayyem Jon Faiz is Director at Inhibrx Biosciences, Inc., Inhibrx, Inc. and BIODESIX INC, and SVP, Research & Development at GenMark Diagnostics, Inc. The declarant has 23 filings in total, and based on the sampled recent filings, the buy and sell amounts are 2487909 and 89867685 EUR between 2016-01-25 and 2025-03-28.